Study guide
3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation
Advanced Oncology Certified Nurse Practitioner AOCNP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide
2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening
2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling
3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging
3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment
4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship
4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence
5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy
5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring
6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies
6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology
7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy
7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies
8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response
8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)
9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety
9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions
10 Chapter 10: Supportive Care - Symptom & Comorbidity Management
10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management
11 Chapter 11: Oncologic Emergencies
11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH
12 Chapter 12: Psychosocial Issues
12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources
13 Chapter 13: Professional Practice & Roles of the APRN
13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education
3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation
Key Takeaways Explain This Topic AI
Core needle biopsy (CNB) or surgical excisional biopsy is essential for preserving tissue architecture required for definitive histopathologic grading and molecular biomarker testing; fine-needle aspiration (FNA) is generally insufficient for primary lymphoma or solid tumor grading.
Biomarker evaluation requires categorizing markers as predictive (estimating response to specific therapies, e.g., EGFR, ALK, HER2, PD-L1) vs. prognostic (estimating overall clinical outcome regardless of therapy, e.g., Ki-67, TP53).
Comprehensive genomic profiling (CGP) via next-generation sequencing (NGS) should be performed on tissue or liquid biopsy (ctDNA) to identify targetable driver mutations, tumor mutational burden (TMB), and microsatellite instability (MSI).
Mismatch repair (MMR) testing via IHC (MLH1, MSH2, MSH6, PMS2) or MSI testing via PCR/NGS is mandatory across solid tumors to evaluate for Lynch syndrome and eligibility for immune checkpoint inhibitor therapy.
Liquid biopsy (circulating tumor DNA [ctDNA]) serves as a non-invasive tool in advanced non-small cell lung cancer (NSCLC) and solid tumors when tissue is inadequate or unfeasible, and for monitoring minimal residual disease (MRD) and secondary resistance mutations.
Last updated: August 2026
1.2 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation
Clinical Blueprint Focus: AOCNP exam candidates must understand the complete diagnostic workflow for solid and hematologic malignancies, including imaging selection (PET-CT, MRI, CT), tissue biopsy acquisition standards, biomarker classification (predictive vs. prognostic), next-generation sequencing (NGS) panels, microsatellite instability testing, and liquid biopsy indications.
Diagnostic Workup & Staging Imaging
Upon clinical suspicion or detection of a mass during screening, a structured diagnostic workup is initiated to establish histology, determine primary organ site, and establish anatomical disease extent (staging).
Imaging Modalities in Oncology Workups
Computed Tomography (CT) with IV & Oral Contrast: The primary workup tool for thoracic, abdominal, and pelvic malignancies. Contrast enhancement evaluates vascular invasion, parenchymal visceral metastases, and lymphadenopathy (defined as lymph nodes ≥1.0 cm in short axis).
Positron Emission Tomography / Computed Tomography (18F-FDG PET-CT): Evaluates metabolic glucose avidity using Fluorodeoxyglucose (FDG). Indicated for initial staging, occult primary search, radiation therapy planning, and treatment response assessment (Deauville criteria in lymphoma; PERCIST criteria in solid tumors). Caution: Granulomatous disease (TB, sarcoidosis) and infection can produce false-positive FDG uptake.
Magnetic Resonance Imaging (MRI): Gold standard modality for evaluating central nervous system (CNS) tumors, brain metastases, spinal cord compression, soft tissue sarcomas, pelvic malignancies (rectal, cervical, prostate), and hepatic lesion characterization.
Radionuclide Bone Scan (Technetium-99m Methylene Diphosphonate [99mTc-MDP]): Detects osteoblastic bone turnover in prostate cancer, breast cancer, and blastic skeletal metastases.
Tissue Biopsy Principles & Acquisition Techniques
Definitive cancer diagnosis requires tissue acquisition prior to initiating systemic chemotherapy, targeted therapy, or radiation. Selecting the correct biopsy modality is vital to obtain adequate tissue volume and preserve cellular architecture.
Biopsy Modality Description & Indications Advantages Limitations / Pitfalls
Core Needle Biopsy (CNB) Uses a hollow 14–18 gauge needle to extract intact tissue cores under ultrasound, CT, or stereotactic guidance. Preferred for breast, lung, liver, kidney, and soft tissue masses. Preserves tissue architecture; adequate volume for IHC and NGS molecular panels. Small risk of hemorrhage, pneumothorax (lung), or tumor seeding (rare).
Fine-Needle Aspiration (FNA) Uses a fine 22–25 gauge needle to aspirate individual cells for cytologic evaluation. Common in thyroid nodules and palpable lymph node staging (EBUS-TBNA). Minimally invasive; rapid on-site evaluation (ROSE) available. Lacks tissue architecture. Insufficient for primary lymphoma classification, soft tissue sarcoma grading, or extensive NGS testing.
Excisional Biopsy Complete surgical removal of an entire suspicious lesion or intact lymph node. Standard of care for suspected lymphoma and melanoma (full-thickness punch or excisional). Provides complete diagnostic specimen and architectural context. Requires minor surgical procedure or operating room access.
Incisional Biopsy Surgical removal of a wedge section of a large tumor mass when excisional removal is unfeasible. Used in large soft tissue sarcomas. Obtains ample tissue volume. Risk of wound breakdown or local hematoma.
Biomarker Evaluation: Predictive vs. Prognostic
Precision oncology relies on molecular biomarker characterization to guide prognosis and predict treatment response.
Predictive Biomarkers: Provide information regarding the likelihood of response or benefit from a specific therapeutic intervention . Examples:
HER2/neu (ERBB2) overexpression/amplification predicts response to anti-HER2 targeted agents (trastuzumab, pertuzumab, fam-trastuzumab deruxtecan-nxki).
EGFR Exon 19 deletion / L858R mutation predicts sensitivity to EGFR tyrosine kinase inhibitors (osimertinib).
PD-L1 tumor proportion score (TPS) predicts efficacy of anti-PD-1/PD-L1 checkpoint inhibitors (pembrolizumab).
Prognostic Biomarkers: Provide information regarding overall patient outcome, disease aggressiveness, or recurrence risk regardless of the specific treatment administered . Examples:
High Ki-67 proliferation index indicates aggressive cellular proliferation and worse overall survival.
TP53 mutation or deletion 17p in chronic lymphocytic leukemia (CLL) confers poor clinical prognosis.
Key Targetable Biomarkers in Major Solid Tumors Solid Tumor Type Key Genomic & Protein Biomarkers Targeted Therapy Class
- ----------------- ---------------------------------- ----------------------
- Non-Small Cell Lung EGFR, ALK, ROS1, BRAF V600E, RET, MET, TKIs (Osimertinib, Alectinib,
- (NSCLC) KRAS G12C, NTRK, PD-L1 Sotorasib, Dabrafenib/Trametinib)
- Colorectal Cancer KRAS/NRAS/BRAF (Wildtype vs Mutant), Anti-EGFR mAbs (Cetuximab),
- (CRC) HER2, MSI-H/dMMR, NTRK BRAF inhibitor (Encorafenib)
- Breast Cancer ER/PR, HER2, BRCA1/2, PIK3CA, ESR1, Endocrine tx, CDK4/6i, PARPi,
- TMB, Trop-2 Alpelisib, ADCs (T-DXd, SG)
- Melanoma BRAF V600E/K, KIT, NRAS, PD-L1 BRAF/MEK inhibitors, Anti-PD-1
- Microsatellite Instability (MSI) & Mismatch Repair (MMR)
Mechanism: DNA mismatch repair (MMR) proteins (MLH1, MSH2, MSH6, PMS2) correct single-base mismatches and insertion-deletion loops during DNA replication. Loss of function in any MMR protein leads to mismatch repair deficiency (dMMR) and accumulation of hypermutable microsatellite repeats (MSI-High).
Testing Methods: Immunohistochemistry (IHC) tests for nuclear expression of the 4 MMR proteins (loss of protein signal = dMMR). Polymerase chain reaction (PCR) or NGS measures microsatellite instability directly (MSI-H).
Clinical Significance:
Therapeutic Selection: MSI-H/dMMR solid tumors express high neoantigen burden, rendering them highly sensitive to anti-PD-1 checkpoint inhibitors (pembrolizumab, dostarlimab) under tumor-agnostic FDA approvals.
Hereditary Screening: Loss of MLH1/PMS2 or MSH2/MSH6 signal serves as the initial screening step for Lynch Syndrome (Hereditary Non-Polyposis Colorectal Cancer).
Next-Generation Sequencing (NGS) & Liquid Biopsy
Comprehensive Genomic Profiling (CGP): Multi-gene NGS panels sequence hundreds of cancer-related genes simultaneously, detecting single nucleotide variants (SNVs), copy number alterations (CNAs), insertion-deletions (indels), genomic fusions (e.g., NTRK , RET , ALK ), Tumor Mutational Burden (TMB ≥10 mutations/megabase), and MSI status.
Liquid Biopsy (Circulating Tumor DNA [ctDNA]): Analyzes cell-free tumor DNA shed into peripheral blood by dying malignant cells.
Clinical Indications: Used when tissue biopsy is unfeasible or carries high surgical risk; when tissue volume is exhausted; for rapid biomarker identification in advanced NSCLC; and for monitoring minimal residual disease (MRD) or acquired resistance mechanisms (e.g., EGFR T790M or C797S , ESR1 mutations).
Key Diagnostic Rule: Liquid biopsy has high positive predictive value (a positive result is actionable), but a high false-negative rate (up to 20–30% due to low tumor shedding). Therefore, a negative liquid biopsy result MUST be followed by a tissue biopsy.